News
Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b
AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b
Amolyt Pharma Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
Amolyt Pharma Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
enGene (Nasdaq: ENGN) Launched as Publicly Traded Genetic Medicines Company
Ironwood Enters into Definitive Agreement to Acquire VectivBio
Ironwood Enters into Definitive Agreement to Acquire VectivBio
Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study
CTI raises $100-million to invest in early-stage Canadian life sciences
Recent news coverage relating to the close of our third fund
CTI LIFE SCIENCES FUND HOLDS $100M INITIAL CLOSE FOR 3RD FUND
Recent news coverage relating to the close of our third fund
CTI Life Sciences unveils new fund
Recent news coverage relating to the close of our third fund
Luca Santarelli's VectivBio
Luca Santarelli's VectivBio buys out small Massachusetts biotech, redoubling focus on metabolic disease
CTI Life Sciences Fund
CTI Life Sciences Fund Successfully Raises $100 Million As A First Tranche of its Third Venture Capital Fund
Bristol Myers Squib
Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis
VectivBio Announces
VectivBio Announces First Patient Dosed in Pivotal Phase 3 Trial of Apraglutide for the Treatment of Short Bowel Syndrome
Pfizer Doses
Pfizer Doses First Patients as Part of Global Achondroplasia Phase 2 Development Program
Find Therapeutics
Find Therapeutics, a new drug development company dedicated to breakthrough therapies against rare diseases launches in Montreal